Finally, given that reduced plasma adropin levels are associated with several diseases, including diabetes, atherosclerosis, polycystic ovary syndrome, and multiple sclerosis, and correlate with disease progression, many researchers propose that adropin could serve as a serum biomarker. Here, ENHO is linked to multiple sclerosis.